Published by Global Banking & Finance Review®
Posted on March 2, 2026
1 min readLast updated: April 2, 2026
Add as preferred source on GoogleNovo Nordisk is investing €432 million (about $506 million) to expand its Athlone, Ireland facility to boost production of oral GLP‑1 drugs like Wegovy and Ozempic for markets outside the U.S., with phased completion expected between late 2027 and 2028.
(Corrects headline to $506 million, not $470 million; corrects text to 432 million euros, not more than 400 million)
COPENHAGEN, March 2 (Reuters) - Novo Nordisk said on Monday it will invest 432 million euros ($506.3 million) to expand its manufacturing facility in Athlone, Ireland.
($1 = 0.8530 euros)
(Reporting by Stine Jacobsen, editing by Louise Rasmussen)
Novo Nordisk is investing 432 million euros ($506.43 million) to expand its manufacturing facility in Athlone, Ireland.
The expansion will focus on increasing production capacities for oral GLP-1 drugs such as Wegovy and Ozempic.
The construction will be finalised gradually from the end of 2027 through 2028.
The expansion aims to strengthen Novo Nordisk's ability to meet current and future demand for oral products outside the U.S.
Explore more articles in the Finance category
